In-vitro antiproliferative activities and kinase inhibitory potencies of meridianin derivatives

Anti-Cancer Drugs

Volumn 19, Issue 8, 2008, Pages 789-792

  Rossignol, Emilie ^a   Debiton, Eric ^a   Fabbro, Doriano ^b   Moreau, Pascale ^a   Prudhomme, Michelle ^a   Anizon, Fabrice ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antitumor agents; In vitro antiproliferative activities; Kinase inhibitory activities; Meridianins

Indexed keywords

ABELSON KINASE; ALKALOID DERIVATIVE; C SRC PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN A; MERIDIANIN A; MERIDIANIN B; MERIDIANIN C; MERIDIANIN D; MERIDIANIN DERIVATIVE; MERIDIANIN E; MERIDIANIN F; MERIDIANIN G; PROTEIN HER 1; PROTEIN KINASE; PROTEIN RET; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; ENZYME INHIBITOR; INDOLE ALKALOID; OXAZINE DERIVATIVE; PHOSPHOTRANSFERASE; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; RESAZURIN; XANTHENE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN MCF 7; CYTOLYSIS; DRUG POTENCY; DRUG SCREENING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; ADENOCARCINOMA; BREAST TUMOR; CELL CULTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; FIBROBLAST; FLOW CYTOMETRY; FLUOROMETRY; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; ENZYME INHIBITORS; FEMALE; FIBROBLASTS; FLOW CYTOMETRY; FLUOROMETRY; HUMANS; INDICATORS AND REAGENTS; INDOLE ALKALOIDS; OXAZINES; PHOSPHOTRANSFERASES; PROTEIN KINASE C; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; XANTHENES;

EID: 53749085771     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32830ce4d8     Document Type: Article

References (12)

1. Liao JJ-L. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem 2007; 50:409-424.
2. Hernández Franco LH, Bal de Kier Joffé E, Puricelli L, Tatian M, Seldes AM, Palermo JA. Indole alkaloids from the tunicate Aplidium meridianum. J Nat Prod 1998; 61:1130-1132.
3. Seldes AM, Rodriguez Brasco MF, Hernández Franco L, Palermo JA. Identification of two meridianins from the crude extract of the tunicate Aplidium meridianum by tandem mass spectrometry. Nat Prod Res 2007; 21:555-563.
4. Gompel M, Leost M, Bal de Kier Joffé E, Puricelli L, Franco LH, Palermo J, Meijer L. Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum. Bioorg Med Chem Lett 2004; 14:1703-1707.
5. Bettayeb K, Tirado OM, Marionneau-Lambot S, Ferandin Y, Lozach O, Morris JC, et al. Meriolins, a new class of cell death-inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res 2007; 67:8325-8334.
6. Radwan MAA, El-Sherbiny M. Synthesis and antitumor activity of indolylpyrimidines: marine natural product meridianin D analogues. Bioorg Med Chem 2007; 15:1206-1211.
7. Rossignol E, Youssef A, Moreau P, Prudhomme M, Anizon F. Synthesis of aminopyrimidylindoles structurally related to meridianins. Tetrahedron 2007; 63:10169-10176.
8. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60:2178-2189.
9. Bold G, Altmann K-H, Bruggen J, Frei J, Lang M, Manley PW, et al. New anilinophtalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J Med Chem 2000; 43:2310-2323. Erratum in: J Med Chem 2000; 43:3200.
10. García-Echeverría C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, et al. In vivo antitumor activity of NVP-AEW541 - A novel, potent, and selective inhibitor of the IGF-1R kinase. Cancer Cell 2004; 5:231-239.
11. Soni R, Fretz H, Muller L, Schoepfer J, Chaudhuri B. Novel CDK inhibitors restore TGF-β sensitivity in CDK4 overexpressing epithelial cells. Biochem Biophys Res Commun 2000; 272:794-800.
12. Jiang B, Yang C-G, Xiong W-N, Wang J. Synthesis and cytotoxicity evaluation of novel indolylpyrimidines and indolylpyrazines as potential antitumor agents. Bioorg Med Chem 2001; 9:1149-1154.